Was the Editas Medicine (EDIT) CFO’s share sale part of a trading plan?

Yes. The filing states the sale was executed under a durable automatic sales instruction plan adopted on July 7, 2022. Such plans typically schedule transactions in advance, making them more routine and less indicative of short-term views on the company’s stock price.

What price range applied to the Editas Medicine (EDIT) CFO’s share sale?

The transaction was completed in multiple trades at prices ranging from $2.7010 to $2.7049 per share. The Form 4 reports the weighted average price of $2.7010, and the CFO has committed to provide full trade details upon request to regulators or shareholders.

Editas Medicine (EDIT) CFO logs small automatic tax-related share sale

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Editas Medicine, Inc. senior vice president and chief financial officer Amy Parison reported an open-market sale of 464 shares of common stock on June 3, 2026 at a weighted average price of $2.7010 per share. According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 7, 2022 and was made to satisfy tax withholding obligations arising from vesting of restricted stock units on June 2, 2026, rather than as a discretionary trade. Following this transaction, she directly holds 14,970 shares of Editas Medicine common stock.

Insider Trade Summary 10b5-1

Net Seller: 464 shares ($1,253)

Net Sell 1 txn

Insider Parison Amy

Role SVP, Chief Financial Officer

Sold 464 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock	464	$2.701	$1K

Holdings After Transaction: Common Stock — 14,970 shares (Direct, null)

Footnotes (1)

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7049. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 464 shares Sale price: $2.7010 per share Shares held after sale: 14,970 shares +2 more

5 metrics

Shares sold 464 shares Open-market sale on June 3, 2026

Sale price $2.7010 per share Weighted average transaction price

Shares held after sale 14,970 shares Direct holdings following transaction

Plan adoption date July 7, 2022 Durable automatic sales instruction plan

RSU vesting date June 2, 2026 Triggered tax withholding sale

Key Terms

durable automatic sales instruction plan, restricted stock units, weighted average purchase price

3 terms

durable automatic sales instruction plan financial

"Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022"

restricted stock units financial

"tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average purchase price financial

"The price reported above reflects the weighted average purchase price"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 04:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last)

(First)

(Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02141

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		S⁽¹⁾		464	D	$2.701⁽²⁾	14,970	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7049. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Amy Parison	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Editas Medicine (EDIT) CFO Amy Parison report in this Form 4?

Editas Medicine CFO Amy Parison reported selling 464 shares of common stock. The shares were sold in the open market under a pre-established automatic sales plan to cover tax withholding from restricted stock unit vesting, not as a discretionary investment decision.

How many Editas Medicine (EDIT) shares did the CFO sell and at what price?

The CFO sold 464 Editas Medicine common shares at a weighted average price of $2.7010. The transaction occurred in multiple trades within a narrow price range, and the weighted average price is the figure reported for this Form 4 filing.

Why did Editas Medicine (EDIT) CFO Amy Parison sell shares on June 3, 2026?

She sold shares to satisfy tax withholding obligations from restricted stock units that vested on June 2, 2026. The sale was executed under a durable automatic sales instruction plan, indicating it was pre-arranged and not a discretionary market-timing trade by the CFO.

How many Editas Medicine (EDIT) shares does the CFO hold after this transaction?

After the reported sale, the CFO directly holds 14,970 shares of Editas Medicine common stock. This post-transaction balance, disclosed in the Form 4, helps show the sale’s relatively small size compared with her remaining direct equity position in the company.